Former Managing Editor Mary Todd reflects on JTO’s 20th anniversary and thanks the editors, authors, reviewers, and publishers who have helped advance science and patient care along the way.
#JTO20#ThoracicOncology#IASLC
Behind the scenes of JTO Insights Podcast Ep. 6: we've got both Editors-in-Chief in the house!
EICs #JTO@DrAlexAdjei & #JTOCRR Emily Stone w/ co-host @TommyJohn00 & podcast team Laura Woodruff @CMPR
📆Tune in on June 25
🔗https://t.co/DOycZiO67w
#JTO20@IASLC@JTOonline
T-5 days until the @IASLC Hot Topics Meeting on Immunotherapy Resistance in Dublin ☘️
Join us for 2 days of top-class learning at the famous @tcddublin. IASLC membership free for students & trainees
Register here 👉🏻https://t.co/2hCq3peI6n
discount code 👉🏻15FORDE
Thank you to the global thoracic oncology community for publishing, reviewing, reading, and citing this research. Join us at #WCLC26 as we celebrate the 20th Anniversary of JTO and the community behind its impact.
#JTO20#ThoracicOncology#CancerResearch
As we celebrate #JTO20, we recognize @TommyJohn00 for eight years of service and commitment to scientific excellence.
Thank you for your dedication to the Journal!
AURORA-ROS1 real world registry from Australia: ROS1 in 2.2% of NSCLC, median age 58, 64% female, 85% advanced at diagnosis, 14% with brain mets. Across lines, 96% received a ROS1 TKI, 53% on a clinical trial, mPFS 48m with 1L later generation TKIs.
https://t.co/QM8haroQHo
With immunotherapy in NSCLC, long term outcomes remain relevant. 5y update on phase III EMPOWER-Lung 3 trial of 1L chemo +/- cemiplimab @JTOonline: OS 21 vs 13m (HR 0.66); 5y OS rate 19.4% with cemiplimab vs 8.8%. PFS 8.2 vs 5.5m; HR 0.58, RR 44% vs 22%.
https://t.co/v763rIB7VI
Our new @JTOonline publication led by @alvaroonco
After progression on RET inhibitors, continuing RET inhibition + chemo may outperform chemoIO:
▫️PFS: 7.8 v 3.5 mo (HR 0.24)
▫️ORR: 38% v 25%
More hematologic toxicity, but encouraging strategy that warrants prospective study.
Today we celebrate Emily Stone, whose seven years of service helped strengthen JTO and support progress in thoracic oncology. Thank you Emily for your service to the Journal! #JTO20
In this study, Zanghì et al. used peripheral blood mononuclear cell profiling to personalize LDCT screening intervals to combat false positives and increase accuracy.
📑Read more: https://t.co/russfbk5bF
@IstTumori
🎧 In the latest #JTOInsights, Drs. @DrAlexAdjei and @TommyJohn00 are joined by Drs. Natasha B. Leighl and Gabriella Sozzi to discuss plasma ctDNA in high-risk stage I #NSCLC and improving lung cancer screening accuracy. Listen now: https://t.co/gOut1LAkZh
The global #lungcancer community is heading to Seoul for #WCLC26.
Take advantage of Early Bird pricing before June 12 and be part of four days of cutting-edge science, collaboration, and multidisciplinary learning.
Register today: https://t.co/pFJaBKvqSA